We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+1.53%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$505M
AUM Growth
+$162M
Cap. Flow
+$166M
Cap. Flow %
32.79%
Top 10 Hldgs %
36.69%
Holding
110
New
32
Increased
27
Reduced
17
Closed
21

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.7M
2
JNJ icon
Johnson & Johnson
JNJ
+$16.9M
3
AMN icon
AMN Healthcare
AMN
+$14.3M
4
CI icon
Cigna
CI
+$14.3M
5
ALBO
Albireo Pharma Inc
ALBO
+$13.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.84M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.57M
3
RCM
R1 RCM Inc. Common Stock
RCM
+$8.51M
4
LLY icon
Eli Lilly
LLY
+$7.54M
5
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 74.38%
2 Consumer Staples 0.82%
3 Financials 0.57%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
51
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.62M 0.52%
34,424
– –
CCRN
52
DELISTED
Cross Country Healthcare
CCRN
$2.6M 0.52%
+401,235
New +$2.54M
AVTX icon
53
Avalo Therapeutics
AVTX
$989M
$2.35M 0.46%
358
+11
+3% +$82.7K
NBSE
54
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$2.31M 0.46%
15,219
+6,249
+70% +$1.02M
ESPR
55
DELISTED
Esperion Therapeutics
ESPR
$2.29M 0.45%
61,600
– –
OYST
56
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$2.23M 0.44%
+105,803
New +$2.47M
DTIL icon
57
Precision BioSciences
DTIL
$191M
$2.19M 0.43%
11,865
+5,697
+92% +$1.13M
VNDA icon
58
Vanda Pharmaceuticals
VNDA
$308M
$2.02M 0.4%
209,205
+65,091
+45% +$696K
GWPH
59
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2M 0.4%
20,501
-74,483
-78% -$8.57M
AGIO icon
60
Agios Pharmaceuticals
AGIO
$1.91B
$1.96M 0.39%
+56,000
New +$2.45M
AYLA
61
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$1.84M 0.37%
159,966
+45,420
+40% +$531K
ATNM icon
62
Actinium Pharmaceuticals
ATNM
$24.7M
$1.83M 0.36%
189,062
-82,526
-30% -$910K
ODT
63
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$1.81M 0.36%
+135,000
New +$3.82M
NTUS
64
DELISTED
Natus Medical Inc
NTUS
$1.78M 0.35%
+103,825
New +$1.96M
CLRB icon
65
Cellectar Biosciences
CLRB
$20.1M
$1.69M 0.34%
4,548
+3,916
+620% +$1.55M
DYAI icon
66
Dyadic International
DYAI
$37.2M
$1.58M 0.31%
209,064
– –
SYRE icon
67
Spyre Therapeutics
SYRE
$9.12B
$1.5M 0.3%
8,444
– –
SYRS
68
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.47M 0.29%
16,678
-10,612
-39% -$1.21M
VREX icon
69
Varex Imaging
VREX
$516M
$1.47M 0.29%
+115,394
New +$1.58M
LITS
70
Lite Strategy Inc
LITS
$31.6M
$1.4M 0.28%
22,402
+20,000
+833% +$1.21M
HROW icon
71
Harrow
HROW
$1.49B
$1.33M 0.26%
238,623
– –
BCEL
72
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.1M 0.22%
78,768
+57,245
+266% +$854K
CRBP icon
73
PUT
Corbus Pharmaceuticals
CRBP
$180M
$1M 0.2%
+18,533
New +$3.36M
AHACU
74
DELISTED
Alpha Healthcare Acquisition Corp Unit
AHACU
$992K 0.2%
+100,000
New +$995K
KURA icon
75
Kura Oncology
KURA
$824M
$959K 0.19%
31,283
-11,400
-27% -$252K
1 2
3
4 5

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return

Sio Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sio Capital Management held 110 positions worth $505M, up 47% from $343M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sio Capital Management deployed $166M of net new capital in Q3 2020, opening 32 new positions and adding to 27 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 76% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $8.57M trimmed.

  • Sio Capital Management's largest Q3 2020 buy was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.
  • Sio Capital Management added most to HILL-ROM HOLDINGS, INC. in Q3 2020, an estimated $10.8M increase.
  • Sio Capital Management's biggest Q3 2020 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $8.57M.
  • Sio Capital Management fully exited Merck in Q3 2020, selling an estimated $8.84M.
  • Sio Capital Management's ten largest holdings make up 37% of its $505M portfolio in Q3 2020.
  • Sio Capital Management opened 32 new positions and closed 21 in Q3 2020.
  • Sio Capital Management's portfolio value rose 47% quarter-over-quarter to $505M.

Based on Sio Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.